You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK)擬與華山醫院進行戰略合作 促進用於腫瘤治療硼中子捕獲技術發展

格隆匯11月9日丨中國生物科技服務(08037.HK)公吿,於2022年11月9日,公司與上海復旦大學附屬華山醫院("華山醫院")訂立合作框架協議,據此訂約各方同意在不同範疇進行戰略合作,以促進用於腫瘤治療硼中子捕獲技術("BNCT")發展,從而為癌症患者提供更高質量醫療服務。

訂約各方同意在學術交流、技術轉移、臨牀治療和其他範疇進行合作,以促進在中華人民共和國推廣BNCT腫瘤治療技術共同目標。訂約各方特地同意在(除其他事項外)以下事項進行合作:

(1)華山醫院同意為中國海南BNCT治療中心建設及運營提供專業指導及建議,以加快在海南建設BNCT中心以及在中國其他地方推廣BNCT治療。公司通過鵬博(海南)硼中子醫療科技有限公司(一家根據中國法律成立公司,為公司間接全資附屬公司)("鵬博海南")投資於該治療中心。華山醫院亦同意其專家在認為適當情況可安排晚期癌症患者在BNCT中心接受治療;

(2)訂約各方同意在中國海南鵬博樂成BNCT中心共同建立一個BNCT研究院,以開展BNCT項目學術交流及科學研究、培養臨牀人才、實施技術轉移及應用,以及聯合發表研究報吿。公司同意為上述BNCT研究院建設及發展提供科研經費;

(3)訂約各方同意加快在臨牀研究和成果應用方面的合作,以獲得新適應症的監管批准;及(4)訂約各方亦同意探索潛在合作機會,在中國上海建立一個BNCT研究中心。

董事會相信,通過合作框架協議及合作與華山醫院組建戰略伙伴關係,將有利於集團通過鵬博海南提供BNCT治療服務業務發展,從而令公司及其股東長遠回報得以最大化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account